[
  {
    "ts": "2025-11-10T06:04:51+00:00",
    "headline": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
    "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
    "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
      "content": {
        "id": "5bfa6687-1864-386e-92f9-c665cf7db08e",
        "contentType": "STORY",
        "title": "Walmart (WMT): Evaluating Valuation as Health and E-Commerce Moves Drive Analyst Optimism",
        "description": "",
        "summary": "Walmart (WMT) is making headlines with several strategic moves, including a major collaboration to provide Eli Lilly’s Zepbound obesity treatment at its pharmacies. These initiatives highlight the company’s expanding role in healthcare and its enhanced e-commerce capabilities. See our latest analysis for Walmart. Walmart’s momentum is clearly building, fueled by a run of retail partnerships, digital health launches, and strategic logistics moves that continue to keep it in the spotlight. The...",
        "pubDate": "2025-11-10T06:04:51Z",
        "displayTime": "2025-11-10T06:04:51Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r4r1G1eFsl6QfUy6gLgJHg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nUAELTZkZtSvOC2PvSjdBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4559202443400de02cb22c3c39f33e03.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/walmart-wmt-evaluating-valuation-health-060451515.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T09:34:31+00:00",
    "headline": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
    "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
    "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "13183824-c983-379b-a43a-0e431e9f2a02",
      "content": {
        "id": "13183824-c983-379b-a43a-0e431e9f2a02",
        "contentType": "STORY",
        "title": "SanegeneBio and Lilly sign RNAi licence deal for metabolic diseases",
        "description": "",
        "summary": "SanegeneBio is responsible for discovering and identifying optimised RNAi molecules for each programme through its LEAD platform.",
        "pubDate": "2025-11-10T09:34:31Z",
        "displayTime": "2025-11-10T09:34:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5",
          "originalWidth": 1440,
          "originalHeight": 812,
          "caption": "SanegeneBio pipeline features experimental treatments for cardiometabolic conditions",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjZc0yDiT_LqG1mGmyb3mg--~B/aD04MTI7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 1440,
              "height": 812,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_8U_5jt8oe1aTOiIv2TJBA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/592a0da246107755dbf22c0c00aba0d5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/sanegenebio-lilly-rnai-licensing-deal/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sanegenebio-lilly-sign-rnai-licence-093431595.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-10T04:33:52+00:00",
    "headline": "2 Growth Stocks with All-Star Potential and 1 We Question",
    "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
    "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
      "content": {
        "id": "7165ce2f-8fe2-3a7a-a332-48252a30a9dd",
        "contentType": "STORY",
        "title": "2 Growth Stocks with All-Star Potential and 1 We Question",
        "description": "",
        "summary": "Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.",
        "pubDate": "2025-11-10T04:33:52Z",
        "displayTime": "2025-11-10T04:33:52Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe",
          "originalWidth": 2400,
          "originalHeight": 1603,
          "caption": "DDOG Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9u.pYFSeNAk6XGh8hFOPaw--~B/aD0xNjAzO3c9MjQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 2400,
              "height": 1603,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/avylLmnwtDoHvc_qca5ARQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/d8f64cd512750e81ddb9293784033ffe.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-growth-stocks-star-potential-043352171.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "USPH"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DDOG"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]